Viatris is a global healthcare company that produces high-quality medicines across a range of therapeutic areas, focusing on both noncommunicable and infectious diseases.

Viatris

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Dec 6, 2024 4:34 AM	4b9be3e8
public peers	general	Sep 27, 2024 1:25 PM	b44ddcfb
news daily refresh	general	Dec 4, 2024 2:16 PM	2cc4c19b
news processing daily refresh	general	Dec 5, 2024 5:50 AM	4dc9da9f
news impact assignment daily	general
news processing basic	general	Dec 5, 2024 5:54 AM	1e8fcde5
company summary	general
signals	general	Sep 27, 2024 1:25 PM	80bc56df
crunchbase trigger	general	Nov 27, 2024 12:50 PM	9c92ed1b
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Sep 27, 2024 1:25 PM	27cc9833
news basic	general	Dec 4, 2024 2:13 PM	bd5869ca
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:VIATRIS

Viatris

Last Close

13.13

22/11 21:00

Market Cap

12.97B

Beta: -

Volume Today

8.36M

Avg: -